329 related articles for article (PubMed ID: 8381725)
1. Role of platelet-activating factor in hypotension and platelet activation induced by infusion of thrombolytic agents in rabbits.
Montrucchio G; Alloatti G; Mariano F; Lupia E; Lucchina PG; Musso E; Emanuelli G; Camussi G
Circ Res; 1993 Mar; 72(3):658-70. PubMed ID: 8381725
[TBL] [Abstract][Full Text] [Related]
2. Streptokinase induces intravascular release of platelet-activating factor in patients with acute myocardial infarction and stimulates its synthesis by cultured human endothelial cells.
Montrucchio G; Bergerone S; Bussolino F; Alloatti G; Silvestro L; Lupia E; Cravetto A; Di Leo M; Emanuelli G; Camussi G
Circulation; 1993 Oct; 88(4 Pt 1):1476-83. PubMed ID: 8403295
[TBL] [Abstract][Full Text] [Related]
3. Pharmacological actions of Y-24180, a new specific antagonist of platelet activating factor (PAF): II. Interactions with PAF and benzodiazepine receptors.
Takehara S; Mikashima H; Muramoto Y; Terasawa M; Setoguchi M; Tahara T
Prostaglandins; 1990 Dec; 40(6):571-83. PubMed ID: 1965554
[TBL] [Abstract][Full Text] [Related]
4. Biochemical and pharmacological activities of SR 27417, a highly potent, long-acting platelet-activating factor receptor antagonist.
Herbert JM; Bernat A; Valette G; Gigo V; Lale A; LaPlace MC; Lespy L; Savi P; Maffrand JP; Le Fur G
J Pharmacol Exp Ther; 1991 Oct; 259(1):44-51. PubMed ID: 1656029
[TBL] [Abstract][Full Text] [Related]
5. Platelet-activating factor (PAF) receptor antagonists inhibit arachidonic acid induced platelet aggregation in rabbit whole blood.
Ammit AJ; O'Neill C
Lipids; 1991 Dec; 26(12):1189-92. PubMed ID: 1668116
[TBL] [Abstract][Full Text] [Related]
6. Pharmacological properties of YM461, a new orally active platelet-activating factor antagonist.
Yamada T; Saito M; Mase T; Hara H; Nagaoka H; Murase K; Tomioka K
Lipids; 1991 Dec; 26(12):1179-83. PubMed ID: 1668114
[TBL] [Abstract][Full Text] [Related]
7. Effects of WEB 2086, an antagonist to the receptor for platelet-activating factor (PAF), on PAF-induced responses in the horse.
Foster AP; Lees P; Andrews MJ; Cunningham FM
Equine Vet J; 1992 May; 24(3):203-7. PubMed ID: 1318830
[TBL] [Abstract][Full Text] [Related]
8. Tissue-type plasminogen activator and streptokinase induce platelet hyperaggregability in the rabbit.
Ohlstein EH; Storer B; Fujita T; Shebuski RJ
Thromb Res; 1987 May; 46(4):575-85. PubMed ID: 3112993
[TBL] [Abstract][Full Text] [Related]
9. Effect of Y-24180, a long-acting antagonist to platelet-activating factor (PAF), on PAF-induced reactions: a relationship between the partial structure of the compound and its duration of the action.
Kagoshima M; Tomomatsu N; Iwahisa Y; Yamaguchi S; Kawakami Y; Terasawa M
Pharmacology; 1997 May; 54(5):261-70. PubMed ID: 9380772
[TBL] [Abstract][Full Text] [Related]
10. Effects of antiplatelet agents on platelet aggregation induced by platelet--activating factor (PAF) in human whole blood.
Chan WP; Levy JV
Prostaglandins; 1991 Oct; 42(4):337-42. PubMed ID: 1665568
[TBL] [Abstract][Full Text] [Related]
11. Plasmin promotes an endothelium-dependent adhesion of neutrophils. Involvement of platelet activating factor and P-selectin.
Montrucchio G; Lupia E; De Martino A; Silvestro L; Savu SR; Cacace G; De Filippi PG; Emanuelli G; Camussi G
Circulation; 1996 Jun; 93(12):2152-60. PubMed ID: 8925584
[TBL] [Abstract][Full Text] [Related]
12. The benzodiazepine receptor ligands RO 5-4864 and RO 15-1788 do not block the inhibition of PAF-induced platelet aggregation seen with the hetrazepine WEB2086.
Griffin K; Hong T; Levy JV
Biochem Biophys Res Commun; 1989 Apr; 160(1):263-7. PubMed ID: 2540748
[TBL] [Abstract][Full Text] [Related]
13. Temporal effects of thrombolytic agents on platelet function in vivo and their modulation by prostaglandins.
Rudd MA; George D; Amarante P; Vaughan DE; Loscalzo J
Circ Res; 1990 Nov; 67(5):1175-81. PubMed ID: 2146037
[TBL] [Abstract][Full Text] [Related]
14. Characterization of receptors for platelet-activating factor on platelets, polymorphonuclear leukocytes and macrophages.
Stewart AG; Dusting GJ
Br J Pharmacol; 1988 Aug; 94(4):1225-33. PubMed ID: 2850058
[TBL] [Abstract][Full Text] [Related]
15. Biochemical and pharmacological properties of SR 27388, a dual antioxidant and PAF receptor antagonist.
Herbert JM; Fraisse L; Bachy A; Valette G; Savi P; Laplace MC; Lassalle J; Roche B; Lale A; Keane PE
J Lipid Mediat; 1993 Aug; 8(1):31-51. PubMed ID: 8257776
[TBL] [Abstract][Full Text] [Related]
16. Continuous binding of the PAF molecule to its receptor is necessary for the long-term aggregation of platelets.
Suzuki M; Sugatani J; Ino M; Shimura M; Akiyama M; Yamazaki R; Suzuki Y; Miwa M
Am J Physiol; 1998 Jan; 274(1):C47-57. PubMed ID: 9458712
[TBL] [Abstract][Full Text] [Related]
17. Beneficial effects of TCV-309, a novel potent and selective platelet activating factor antagonist in endotoxin and anaphylactic shock in rodents.
Terashita Z; Kawamura M; Takatani M; Tsushima S; Imura Y; Nishikawa K
J Pharmacol Exp Ther; 1992 Feb; 260(2):748-55. PubMed ID: 1738121
[TBL] [Abstract][Full Text] [Related]
18. In vitro effect of plasmin on human platelet function in plasma. Inhibition of aggregation caused by fibrinogenolysis.
Gouin I; Lecompte T; Morel MC; Lebrazi J; Modderman PW; Kaplan C; Samama MM
Circulation; 1992 Mar; 85(3):935-41. PubMed ID: 1531623
[TBL] [Abstract][Full Text] [Related]
19. Interaction of the Paf antagonist WEB 2086 and its hetrazepine analogues with human platelets and endothelial cells.
Korth R; Hirafuji M; Keraly CL; Delautier D; Bidault J; Benveniste J
Br J Pharmacol; 1989 Oct; 98(2):653-61. PubMed ID: 2555017
[TBL] [Abstract][Full Text] [Related]
20. CIS-19, a novel platelet activating factor receptor antagonist: in vitro and in vivo studies.
Ko FN; Yu SM; Chen IS; Ishii H; Chang YL; Huang TF; Teng CM
Biochim Biophys Acta; 1993 Jan; 1175(2):225-31. PubMed ID: 8380343
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
